Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare negotiations or not. The CMS has until June 1 to send an initial offer for the adjusted prices.

The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction Act. This includes Novo Nordisk's drugs like Ozempic and Wegovy. There are concerns about the policy's impact on innovation and its political implications with the incoming administration.

Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,